Advertisement
Advertisement
U.S. markets close in 2 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Imagin Medical Inc. (IME.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
0.2200-0.0150 (-6.38%)
As of 12:33PM EST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2350
Open0.2200
Bid0.1650 x N/A
Ask0.2200 x N/A
Day's Range0.2200 - 0.2200
52 Week Range0.1200 - 0.5600
Volume10,233
Avg. Volume5,427
Market Cap2.383M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IME.CN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin

      Ponce Therapeutics, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, announced today that it had executed a worldwide, exclusive license to Speratum's proprietary Nano-in™ and No-Pass Mimic™ technologies to advance its lead product, ReBeaut™, a state-of-the-art biotechnology platform to restore the youthful balance of aged or "senescent" and young, vital cells in the skin, targeting the senescent cells for elimination,

    • PR Newswire

      Imagin Medical Announces Stock Option Grants

      Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company") today announced today that, pursuant to the Company's Stock Option Plan, an aggregate of 472,187 shares have been granted to certain employees, board members and consultants as incentive stock options at an exercise price of $0.28 USD per share. The options are exercisable for a period of five years, ending on April 22, 2027.

    Advertisement
    Advertisement